These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19528243)

  • 1. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.
    Ning S; Knox SJ; Harsh GR; Culler MD; Katznelson L
    Endocr Relat Cancer; 2009 Sep; 16(3):1045-55. PubMed ID: 19528243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of somatostatin analogues in rat GH-secreting pituitary tumor cell lines.
    Dicitore A; Saronni D; Gaudenzi G; Carra S; Cantone MC; Borghi MO; Persani L; Vitale G
    J Endocrinol Invest; 2022 Jan; 45(1):29-41. PubMed ID: 34128215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of somatostatin on repair of ionizing radiation-induced DNA damage in pituitary adenoma cells GH3.
    Řezáčová M; Čáp J; Vokurková D; Lukášová E; Vávrová J; Cerman J; Mašín V; Mazánková N
    Physiol Res; 2008; 57(2):225-235. PubMed ID: 17552875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.
    Chahal HS; Trivellin G; Leontiou CA; Alband N; Fowkes RC; Tahir A; Igreja SC; Chapple JP; Jordan S; Lupp A; Schulz S; Ansorge O; Karavitaki N; Carlsen E; Wass JA; Grossman AB; Korbonits M
    J Clin Endocrinol Metab; 2012 Aug; 97(8):E1411-20. PubMed ID: 22659247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
    Padova H; Rubinfeld H; Hadani M; Cohen ZR; Nass D; Taylor JE; Culler MD; Shimon I
    Mol Cell Endocrinol; 2008 May; 286(1-2):214-8. PubMed ID: 18276067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
    Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varying additive effects of bromocriptine with two somatostatin analogs in cultures of GH-secreting adenomas.
    Balsa JA; Varela C; Lucas T; García-Uría J; Barceló B; Sancho-Rof JM
    Horm Metab Res; 2002 Aug; 34(8):435-40. PubMed ID: 12198598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
    Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
    Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro.
    Florio T; Thellung S; Arena S; Corsaro A; Spaziante R; Gussoni G; Acuto G; Giusti M; Giordano G; Schettini G
    Eur J Endocrinol; 1999 Oct; 141(4):396-408. PubMed ID: 10526255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells.
    Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Lamberts SW
    Endocrinology; 1994 Jan; 134(1):301-6. PubMed ID: 7903931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmented Growth Hormone Secretion and Stat3 Phosphorylation in an Aryl Hydrocarbon Receptor Interacting Protein (AIP)-Disrupted Somatotroph Cell Line.
    Fukuda T; Tanaka T; Hamaguchi Y; Kawanami T; Nomiyama T; Yanase T
    PLoS One; 2016; 11(10):e0164131. PubMed ID: 27706259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas.
    Lekva T; Berg JP; Lyle R; Heck A; Ringstad G; Olstad OK; Michelsen AE; Casar-Borota O; Bollerslev J; Ueland T
    Endocrinology; 2013 Sep; 154(9):3331-43. PubMed ID: 23825128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cyclic pentapeptide d-Arg3FC131, a CXCR4 antagonist, induces apoptosis of somatotrope tumor and inhibits tumor growth in nude mice.
    Kim JM; Lee YH; Ku CR; Lee EJ
    Endocrinology; 2011 Feb; 152(2):536-44. PubMed ID: 21147876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells.
    Peverelli E; Giardino E; Mangili F; Treppiedi D; Catalano R; Ferrante E; Sala E; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
    Cancer Lett; 2018 Oct; 435():101-109. PubMed ID: 30098401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preoperative administration of a slow releasing somatostatin analog (SR-lanreotide, BIM 23014) in patients with acromegaly in the course of GH-releasing adenoma].
    Zieliński G; Podgórski JK; Koziarski A; Siwik J; Zgliczyński W; Wieliczko W
    Neurol Neurochir Pol; 2001; 35(3):423-37. PubMed ID: 11732266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lanreotide-conjugated PEG-DSPE micelles: an efficient nanocarrier targeting to somatostatin receptor positive tumors.
    Zheng N; Dai W; Zhang H; Wang X; Wang J; Zhang X; Wang K; Li J; Zhang Q
    J Drug Target; 2015 Jan; 23(1):67-78. PubMed ID: 25366085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs.
    Imam H; Eriksson B; Lukinius A; Janson ET; Lindgren PG; Wilander E; Oberg K
    Acta Oncol; 1997; 36(6):607-14. PubMed ID: 9408151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells.
    Treppiedi D; Mangili F; Giardino E; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Calebiro D; Mantovani G; Peverelli E
    Neuroendocrinology; 2020; 110(7-8):642-652. PubMed ID: 31574507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185.
    Fan X; Mao Z; He D; Liao C; Jiang X; Lei N; Hu B; Wang X; Li Z; Lin Y; Gou X; Zhu Y; Wang H
    J Endocrinol Invest; 2015 Oct; 38(10):1117-28. PubMed ID: 26036598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.